The role of procalcitonin in adult patients with community-acquired pneumonia - A systematic review

Danish Medical Journal

Volumn 59, Issue 3, 2012, Pages

  Berg, Peter ^a   Lindhardt, Bjarne Ørskov ^a  

^a HILLERØD HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PROCALCITONIN; BIOLOGICAL MARKER; CALCITONIN; PROTEIN PRECURSOR;

BACTERIAL INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; DEATH; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE SEVERITY; DRUG EXPOSURE; HUMAN; META ANALYSIS (TOPIC); PNEUMONIA SEVERITY INDEX; PREDICTION; PRIMARY MEDICAL CARE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCIENTIFIC LITERATURE; SCORING SYSTEM; SYSTEMATIC REVIEW; AGE; BLOOD; COMMUNICABLE DISEASE; HOSPITALIZATION; PATHOLOGY; PHYSIOLOGY; PREDICTIVE VALUE;

ADRENAL CORTEX HORMONES; AGE FACTORS; BIOLOGICAL MARKERS; CALCITONIN; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; SEVERITY OF ILLNESS INDEX;

EID: 84873147056     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Moya F, Nieto A, R-Candela JL. Calcitonin Biosynthesis: evidence for a Precursor. Eur J Biochem 1975;55:407-13.
2. Assicot M, Gendrel D, Carsin H et al. High serum procalcitonin concentrations in patients with sepsis and infection. Lancet 1993, 341: 515-8.
3. Hedlund J, Hansson L-O. Procalcitonin and C-Reactive protein levels in community-acquired pneumonia: correlation with aetiology and prognosis. Infection 2000;28:68-73.
4. Christ-Crain M, Müller B: Procalcitonin in bacterial infections-hype, hope, more or less? Swiss Med Week 2005;135:451-60.
5. Boussekey N, Leroy O, Georges H et al. Diagnostic and prognostic values of admission procalcitonin levels in community-acquired pneumonia in an intensive care unit. Infection 2005;33:257-63.
6. Boussekey N, Leroy O, Alfandari S et al. Procalcitonin kinetics in the prognosis of severe community-acquired pneumonia. Intens Care Med 2006:32:469-72.
7. Heppner HJ, Bertsch T, Alber B et al. Procalcitonin: inflammatory biomarker for assessing the severity of community-acquired pneumonia-a clinical observation in geriatric patients. Gerontology 2010;56:385-9.
8. Okimoto N, Hayashi Y, Ishiga M et al. Procalcitonin and severity of community-acquired pneumonia. J Infect Chemother 2009;15:426-7.
9. Menéndez R, Cavalcanti M, Reyes S et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax 2008;63:447-52.
10. Menéndez R, Martínez R, Reyes S et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax 2009;64:587-91.
11. Müller B, Harbarth S, Stolz D et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia BMC Inf Dis 2007;7:10-20.
12. Hirakata Y, Yanagihara K, Kurihara S et al. Comparison of usefulness of plasma procalcitonin and C-reactive protein measurements for estimation of severity in adults with community-acquired pneumonia. Diagnostic Microb Inf Dis 2008;61:170-4.
13. Huang DT, Weissfeld LA, Kellum JA et al. Risk predicion with procalcitonin and clinical rules in community-acquired pneumonia. Annals Emerg Med 2008;52:48-58.
14. Schuetz P, Suter-Widmer I, Chaudri A et al. Prognostic value of procalcitonin in community-acquired pneumonia. Eur Resp J 2011;37: 384-92.
15. Krüger S, Ewig S, Marre R et al. Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classes. Eur Resp J 2008;31:349-55.
16. Krüger S, Ewig S, Giersdorf S et al. Cardiovascular and inflammatory biomarkers to predict short-and long-term survival in communityacquired pneumonia-results from the German competence network CAPNETZ. Am J Resp Crit Care Med 2010;182:1426-34.
17. Claessens Y-E, Mathevon T, Kierzek G et al. Accuracy of C-reactive protein, procalcitonin, and mid-regional pro-atrial natriuretic peptide to guide site of care of community-acquired pneumonia. Intens Care Med 2010;36:799-809.
18. Schuetz P, Christ-Crain M, Thomann R et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections. JAMA 2009;302:1059-66.
19. Menéndez R, Martínez R, Reyes S et al. Stability in community-acquired pneumonia: one step forward with markers? Thorax 2009;64:987-92.
20. Krüger S, Ewig S, Papassotiriou J et al. Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of aetiology in patients with CAP-results from the German competence network CAPNETZ. Resp Res 2009;10:65-75.
21. Piacentini E, Sánchez B, Arauzo V et al. Procalcitonin levels are lower in intensive care unit patients with H1N1 influenza A virus pneumonia than in those with community-acquired bacterial pneumonia. A pilot study. J Crit Care 2011;26:201-205.
22. Masiá M, Gutiérrez F, Shum C et al. usefulness of procalcitonin levels in community-acquired pneumonia according to the Patients Outcome Research Team Pneumonia Severity Index. Chest 2005;128:2223-9.
23. Nyamande K, Lalloo UG. Serum procalcitonin distinguishes CAP due to bacteria, Mycobacterium tuberculosis and PJP. Int J Tuberc Lung Dis 2006;10:510-15.
24. Jereb M, Kotar T. Usefulness of procalcitonin to differentiate typical from atypical community-acquired pneumonia. Wien Klin Wochenschr 2006;118:170-4.
25. Müller F, Christ-Crain M, Bregenzer T et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia-a prospective cohort trial. Chest 2010;138:121-9.
26. Polzin A, Pletz M, Erbes R et al.: Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis Eur Resp J 2003;21:939-43.
27. Christ-Crain M, Jaccard-Stolz D, Bingisser R et al. Effect of procalcitoninguided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;363:600-7.
28. Tang H, Huang T, Jing J et al. Effect of procalcitonin-guided treatment in patients with infections: a systematic review and meta-analysis. Infection 2009;37:497-507.
29. Bafadhel M, Clark TW, Reid C et al. Procalcitonin and C reactive protein in hospitalised adult patients with community acquired pneumonia, exacerbation of asthma and chronic obstructive pulmonary disease. Chest 2010 (epub ahead of print, Oct 28 2010).
30. Krüger S, Ewig S, Kunde J et al. Assessment of inflammatory markers in patients with community-acquired pneumonia-influence of antimicrobial pre-treatment-results from the German competence network CAPNETZ. Clinica Chimica Acta 2010;411:1929-34.
31. Christ-Crain M, Stolz D, Bingisser R et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia. Crit Care Med 2006;174:84-93.
32. Schuetz P, Batschwaroff M, Dusemund F et al. Effectiveness of a procalcitonin algorithm to guide antibiotic therapy in respiratory tract infections outside of study conditions: a post-study survey Eur J Clin Microbiol Inf Dis 2010;29:269-77.
33. Holm A, Pedersen SS, Nexoe J et al.: Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care British J Gen Prac 2007;57:555-60.
34. Briel M, Schuetz P, Mueller B et al. Procalcitonin-guided antibiotic use vs a standard approach for acute respiratory tract infections in primary care. Arch Intern Med 2008;168:2000-7.
35. Perren A, Cerutti B, Lepori M et al. Influence of steroide on procalcitonin and C-reactive protein in patients with COPD and community-acquired pneumonia. Infection 2008;36:163-6.